65,437 trials
Schizophrenia Spectrum and Other Psychotic Disorders · Mental Disorders, Severe
Primary: Proportion of Patient Participants Who Experience Illness Relapse — 0.27; 0.45 proportion of participants
HSV-2
Primary: Efficacy of 4 Different Doses of AIC316 and Matching Placebo With Respect to the Suppression of Herpes Simplex Virus Replication (Shedding Rate) — 21.2; 9.2; 2.0; 5.2…
Estrogen Levels Among Breast Cancer Patients
Primary: Changes in Serum Estradiol — 3.9 pg/mL
Heart Failure With Preserved Ejection Fraction
Primary: Change in Plasma N-terminal Proatrial Natriuretic Peptide (NT proANP) — 47.4; 46.4 pg/mL
Hemophilia A · Hemophilia B
Primary: Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period — 30.991; 3.133 episodes per participant per year — p=<0.0001
Diabetes Mellitus, Type 2
Primary: Number of Patients With Adverse Drug Reactions (ADRs) — 1029 Participants
Contiguous Stage II Mantle Cell Lymphoma · Noncontiguous Stage II Mantle Cell Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Two-year Disease-free Survival — 90 percentage of participants
Prostate Cancer · Recurrent Prostate Carcinoma · Stage IV Prostate Adenocarcinoma
Primary: Number of Participants With Change in PSA Response — 2; 0 Participants
Stroke
Primary: Change in Ten Minute Walk Test (10MWT) — 0.551 meters per second (m/s) — p=.0001
Pertussis · Pertussis Immunisation
Primary: Number of Participants Experiencing Adverse Events of Special Interest (AESIs) — 0; 0; 0; 0 Participants
Metabolism and Nutrition Disorder · Obesity
Primary: Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks — -0.18; -0.18; -0.50; -0.48 SDS score
Kidney Cancer
Primary: Objective Response Rate — 28.3 percentage of participants
End Stage Renal Disease
Primary: Mean Partial Thromboplastin Time (PTT) at 15 Minutes — 38.4; 38.4; 45.4; 49.7 Seconds
Dry Eye Disease
Primary: Mean Change in Schirmer's Test From Baseline to 28 Days — 10.5; 5.7 mm
Brain Neoplasms
Primary: Progression-free Survival (PFS) Determined by BICR — 10.64; 10.32 Months